159 related articles for article (PubMed ID: 35269844)
21. Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma.
Liu S; Howell P; Ren S; Fodstad O; Zhang G; Samant R; Shevde L; Xi Y; Pannell LK; Riker AI
Clin Exp Metastasis; 2009; 26(7):739-49. PubMed ID: 19488830
[TBL] [Abstract][Full Text] [Related]
22. Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene.
Kang DC; Gopalkrishnan RV; Lin L; Randolph A; Valerie K; Pestka S; Fisher PB
Oncogene; 2004 Mar; 23(9):1789-800. PubMed ID: 14676839
[TBL] [Abstract][Full Text] [Related]
23. Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids.
Koroknai V; Patel V; Szász I; Ádány R; Balazs M
Pathol Oncol Res; 2020 Oct; 26(4):2557-2566. PubMed ID: 32613561
[TBL] [Abstract][Full Text] [Related]
24. [Construction of RNA interference (RNAi) lentiviral expression vector of DEK gene and its effect on the biological behavior of liver cancer cells].
Li SH; Hou Y; Chen Z; Wu WR; Wu CX; Sun H
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):868-875. PubMed ID: 33105933
[No Abstract] [Full Text] [Related]
25. Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin.
Guo H; Prell M; Königs H; Xu N; Waldmann T; Hermans-Sachweh B; Ferrando-May E; Lüscher B; Kappes F
FEBS Lett; 2021 May; 595(10):1438-1453. PubMed ID: 33686684
[TBL] [Abstract][Full Text] [Related]
26. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
27. PTBP1 is a Novel Poor Prognostic Factor for Glioma.
Liu P; He GC; Tan YZ; Liu GX; Liu AM; Zhu XP; Zhou Y; Hu WM
Biomed Res Int; 2022; 2022():7590997. PubMed ID: 35299889
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA SOX2OT maintains the stemness of pancreatic cancer cells by regulating DEK via interacting with miR-200a/141.
Liu CS; Zhou Q; Zhang YD; Fu Y
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2368-2379. PubMed ID: 32196588
[TBL] [Abstract][Full Text] [Related]
29. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
30. Identification of key candidate genes involved in melanoma metastasis.
Chen J; Wu F; Shi Y; Yang D; Xu M; Lai Y; Liu Y
Mol Med Rep; 2019 Aug; 20(2):903-914. PubMed ID: 31173190
[TBL] [Abstract][Full Text] [Related]
31. Immune signatures in cutaneous melanoma correlate with survival independently of immunotherapy treatment.
Johansson PA; Hayward NK; Pritchard AL
Pigment Cell Melanoma Res; 2023 Mar; 36(2):246-251. PubMed ID: 36617535
[TBL] [Abstract][Full Text] [Related]
32. DEK Expression is controlled by E2F and deregulated in diverse tumor types.
Carro MS; Spiga FM; Quarto M; Di Ninni V; Volorio S; Alcalay M; Müller H
Cell Cycle; 2006 Jun; 5(11):1202-7. PubMed ID: 16721057
[TBL] [Abstract][Full Text] [Related]
33. Selected microRNA-192 mutant indicates association with several function genes in bovine cells.
Zi C; Zeng D; Zhou J; Dai J; Jiang L; Xue F; Jiang Y; Li B
Genes Genomics; 2018 Apr; 40(4):361-371. PubMed ID: 29892841
[TBL] [Abstract][Full Text] [Related]
34. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
35. Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling.
Capitano ML; Mor-Vaknin N; Saha AK; Cooper S; Legendre M; Guo H; Contreras-Galindo R; Kappes F; Sartor MA; Lee CT; Huang X; Markovitz DM; Broxmeyer HE
J Clin Invest; 2019 May; 129(6):2555-2570. PubMed ID: 31107242
[TBL] [Abstract][Full Text] [Related]
36. The miR-1204 regulates apoptosis in NSCLC cells by targeting DEK.
Qian Z; Yang J; Liu H; Yin Y; Hou L; Hu H
Folia Histochem Cytobiol; 2019; 57(2):64-73. PubMed ID: 31246264
[TBL] [Abstract][Full Text] [Related]
37. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
38. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
39. Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis.
Chen B; Sun D; Qin X; Gao XH
Invest New Drugs; 2021 Aug; 39(4):928-948. PubMed ID: 33501609
[TBL] [Abstract][Full Text] [Related]
40. CENPE, PRC1, TTK, and PLK4 May Play Crucial Roles in the Osteosarcoma Progression.
Wang F; Zhao Q; Liu W; Kong D
Technol Cancer Res Treat; 2020; 19():1533033820973278. PubMed ID: 33176597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
